Empagliflozin in heart failure patients with reduced ejection fraction: a randomized clinical trial (Empire HF)

Data from recent cardiovascular outcome trials in patients with type 2 diabetes (T2D) suggest that sodium-glucose cotransporter 2 (SGLT2) inhibitors can prevent development of heart failure (HF) and prolong li...

Source: Trials - June 21, 2019 Category: General Medicine Authors: Jesper Jensen, Massar Omar, Caroline Kistorp, Mikael Kj ær Poulsen, Christian Tuxen, Ida Gustafsson, Lars Køber, Finn Gustafsson, Emil Fosbøl, Niels Eske Bruun, Lars Videbæk, Peter Hartmund Frederiksen, Jacob Eifer Møller and Morten Schou Tags: Study protocol Source Type: research